These findings supported the results of the SECOMBIT trial, establishing nivolumab and ipilimumab followed by BRAF and MEK inhibitor combination at disease progression as the preferred treatment sequence for a large majority of patients with advanced BRAF-mutant melanoma. Here, MAP2K7 is linked to melanoma.